Skip to main content

Advertisement

SpringerLink
Log in

Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Intraperitoneal chemotherapy has an established role in the treatment of selected patients with colorectal peritoneal metastases. Oxaliplatin is highly suitable as a chemotherapeutic agent for hyperthermic intraperitoneal chemotherapy (HIPEC), but its use to date has been limited because of the morbidity caused by severe electrolyte and glycemic imbalances associated with 5% glucose as its carrier solution. This report provides an overview of the development, rationale, and application of intraperitoneal chemotherapy and the use of various drugs and carrier solutions. A novel, evidence-based protocol for bidirectional oxaliplatin-based HIPEC in a physiologic carrier solution (Dianeal PD4 dextrose 1.36%) is presented, and its impact on electrolyte and glucose levels is demonstrated.

Methods

After implementation of the new protocol, the serum electrolyte (sodium, potassium, and chloride) levels, glucose levels, and intravenous insulin requirements were intensively measured in eight consecutive cases immediately before HIPEC (T = 0), immediately after HIPEC (T = 30), 1 h after HIPEC (T = 60), and 3 h after HIPEC (T = 180).

Results

The median sodium levels were 140 mmol/L at T = 0, 138 mmol/L at T = 30, 140 mmol/L at T = 60, and 140 mmol/L at T = 180. The respective median potassium levels were 4.6, 4.2, 3.7, and 3.9 mmol/L, and the respective median chloride levels were 112, 111, 111, and 112 mmol/L. The respective median glucose levels were 9, 11.5, 10.7, and 8.6 mmol/L. The median insulin requirements were respectively 0.5, 1.5, 1.2, and 0 U/h. None of the patients were diabetic.

Conclusion

Using a novel protocol for bidirectional oxaliplatin-based HIPEC in Dianeal instead of 5% glucose, the observed fluctuations in this study were minimal and not clinically relevant compared with historical values for electrolyte and glycemic changes using 5% glucose as a HIPEC carrier solution. This novel protocol leads to only minimal and clinically irrelevant electrolyte and glycemic disturbances, and its adoption as the standard protocol for oxaliplatin-based HIPEC should be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Shingleton WW, Parker RT, Mahaley S. Abdominal perfusion for cancer chemotherapy. Ann Surg 1960;152:583–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ryan RF, Krementz ET, Creech O Jr, Winblad JN, Chamblee W, Cheek H. Selected perfusion of isolated viscera with chemotherapeutic agents using an extracorporeal circuit. Surg Forum. 1957;8:158–61.

    CAS  PubMed  Google Scholar 

  3. Hart GD. Palliative management of gastrointestinal cancer. Can Med Assoc Jl. 1964;90:1265–8.

    CAS  Google Scholar 

  4. Vaillant JC, Nordlinger B, Deuffic S, et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: a multicenter phase III trial. Ann Surg. 2000;231:449–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Scheithauer W, Kornek G, Rosen H, et al. Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma. Eur J Cancer. 1995;31A:1981–6.

    Article  CAS  PubMed  Google Scholar 

  6. Scheithauer W, Kornek GV, Marczell A, et al. Combined intravenous and intraperitoneal chemotherapy with fluorouracil+leucovorin vs fluorouracil+levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer. 1998;77:1349–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985;98:414–22.

    CAS  PubMed  Google Scholar 

  8. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–11.

    CAS  PubMed  Google Scholar 

  9. Markman M, Howell SB, Lucas WE, Pfeifle CE, Green MR. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol. 1984;2:1321–6.

    Article  CAS  PubMed  Google Scholar 

  10. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845–51.

    Article  CAS  PubMed  Google Scholar 

  11. Sugarbaker PH, Averbach AM, Jacquet P, Stuart OA, Stephens AD. Hyperthermic intraoperative intreperitoneal chemotherapy (HIIC) with mitomycin C. Surg Technol Int. 1996;5:245–9.

    CAS  PubMed  Google Scholar 

  12. Jacquet P, Stephens AD, Averbach AM, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer. 1996;77:2622–9.

    Article  CAS  PubMed  Google Scholar 

  13. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55:130–8.

    Article  CAS  PubMed  Google Scholar 

  14. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.

    Article  PubMed  Google Scholar 

  15. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.

    Article  PubMed  Google Scholar 

  16. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.

    Article  PubMed  Google Scholar 

  17. Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and HIPEC in The Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20(13):4224–30.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FA. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91:739–46.

    Article  CAS  PubMed  Google Scholar 

  19. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.

    Article  PubMed  Google Scholar 

  20. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.

    Article  PubMed  Google Scholar 

  21. Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617–23.

    Article  CAS  PubMed  Google Scholar 

  22. Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis. 2015;17:772–8.

    Article  CAS  PubMed  Google Scholar 

  23. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.

    Article  PubMed  Google Scholar 

  24. Mirnezami R, Mehta AM, Chandrakumaran K, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014;111:1500–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Cascales-Campos PA, Gil J, Gil E, et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Ann Surg Oncol. 2014;21:2383–9.

    Article  PubMed  Google Scholar 

  26. Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014;14:183.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Le Brun JF, Campion L, Berton-Rigaud D, et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study. Ann Surg Oncol. 2014;21:3621–7.

    Article  PubMed  Google Scholar 

  28. Elias D, Honore C, Dumont F, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011;254:289–93.

    Article  CAS  PubMed  Google Scholar 

  29. Honore C, Goere D, Souadka A, Dumont F, Elias D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:183–92.

    Article  PubMed  Google Scholar 

  30. Klaver CE, Musters GD, Bemelman WA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis: the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15:428.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FA. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev. 2001;27:365–74.

    Article  CAS  PubMed  Google Scholar 

  32. Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 2001;47:269–76.

    Article  CAS  PubMed  Google Scholar 

  33. Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemotherapy. Surg Oncol Clin North Am. 2003;12:813–24.

    Article  Google Scholar 

  34. Mohamed F, Marchettini P, Stuart OA, Yoo D, Sugarbaker PH. A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol. 2003;29:261–5.

    Article  CAS  PubMed  Google Scholar 

  35. Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol. 2003;52:405–10.

    Article  CAS  PubMed  Google Scholar 

  36. Mohamed F, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions. J Surg Res. 2003;113:114–20.

    Article  CAS  PubMed  Google Scholar 

  37. Kusamura S, Dominique E, Baratti D, Younan R, Deraco M. Drugs, carrier solutions, and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008;98:247–52.

    Article  PubMed  Google Scholar 

  38. Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int. 2000;20(Suppl 2):S37–S41.

    PubMed  Google Scholar 

  39. Sun Y, Mills D, Ing TS, Shapiro JI, Tzamaloukas AH. Body sodium, potassium, and water in peritoneal dialysis-associated hyponatremia. Perit Dial Int. 2014;34:253–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Lam JY, McConnell YJ, Rivard JD, Temple WJ, Mack LA. Hyperthermic intraperitoneal chemotherapy+early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Am J Surg. 2015;210(3):424–30.

    Article  PubMed  Google Scholar 

  41. Cashin PH, Graf W, Nygren P, Mahteme H. Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study. Ann Oncol. 2012;2011/06/21:647–52.

    Article  Google Scholar 

  42. Tomasz M, Palom Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther. 1997;1998/04/16:73–87.

    Article  Google Scholar 

  43. Cummings J, Spanswick VJ, Tomasz M, Smyth JF. Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development. Biochem Pharmacol. 1998;1998/10/08:405–14.

    Google Scholar 

  44. Spanswick VJ, Cummings J, Smyth JF. Current issues in the enzymology of mitomycin C metabolic activation. Gen Pharmacol. 1998;1998/10/29:539–44.

    Article  Google Scholar 

  45. Gan Y, Mo Y, Kalns JE, et al. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Clin Cancer Res. 2001;7(5):1313–9.

    CAS  PubMed  Google Scholar 

  46. Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T, Tsuruo T. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res. 1996;1996/06/15:2823–6.

    Google Scholar 

  47. Traver RD, Horikoshi T, Danenberg KD, et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992;52(4):797–802.

    CAS  PubMed  Google Scholar 

  48. Fleming RA, Drees J, Loggie BW, et al. Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C. Pharmacogenet Genom. 2002;12(1):31–7.

    Article  CAS  Google Scholar 

  49. van Ruth S, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin North Am. 2003;12:771–80.

    Article  Google Scholar 

  50. van Ruth S, Mathot RA, Sparidans RW, Beijnen JH, Verwaal VJ, Zoetmulder FA. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokinet. 2004;43:131–43.

    Article  PubMed  Google Scholar 

  51. Verwaal VJ, van TH, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2004;85:61–7.

    Article  PubMed  Google Scholar 

  52. Hompes D, D’Hoore A, Wolthuis A, et al. The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol. 2014;109:527–32.

    Article  CAS  PubMed  Google Scholar 

  53. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002;2002/12/07:227–35.

    Google Scholar 

  54. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;2000/04/25:1205–18.

    Google Scholar 

  55. Jerremalm E, Wallin I, Ehrsson H. New insights into the biotransformation and pharmacokinetics of oxaliplatin. J Pharm Sci. 2009;2009/04/03:3879–85.

    Article  Google Scholar 

  56. Luo FR, Wyrick SD, Chaney SG. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res. 1998;1999/06/15:595–603.

    Google Scholar 

  57. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.

    Article  CAS  PubMed  Google Scholar 

  58. Elias D, Bonnay M, Puizillou JM, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.

    Article  CAS  PubMed  Google Scholar 

  59. Elias D, El OA, Bonnay M, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology. 2002;63:346–52.

    Article  CAS  PubMed  Google Scholar 

  60. Piche N, Leblond FA, Sideris L, et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg. 2011;254:138–44.

    Article  PubMed  Google Scholar 

  61. Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol. 2001;76:106–14.

    Article  CAS  PubMed  Google Scholar 

  62. Elias D, Raynard B, Bonnay M, Pocard M. Heated intraoperative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies. Eur J Surg Oncol. 2006;32:607–13.

    Article  CAS  PubMed  Google Scholar 

  63. Quenet F, Goere D, Mehta SS, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254:294–301.

    Article  PubMed  Google Scholar 

  64. Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res. 2004;21:891–4.

    Article  CAS  PubMed  Google Scholar 

  65. Curis E, Provost K, Bouvet D, et al. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. J Synchrotron Radiat. 2001;8(Pt 2):716–8.

    Article  CAS  PubMed  Google Scholar 

  66. Rueth NM, Murray SE, Huddleston SJ, et al. Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol. 2011;18:174–80.

    Article  PubMed  Google Scholar 

  67. De Somer F., Ceelen W, Delanghe J, et al. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int. 2008;28:61–6.

    PubMed  Google Scholar 

  68. Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De SF, Pattyn P. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol. 2008;15:535–41.

    Article  PubMed  Google Scholar 

  69. Mehta AM, Van den Hoven JM, Rosing H, et al. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm. 2015;479:23–7.

    Article  CAS  PubMed  Google Scholar 

  70. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 2005;31:90–105.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

There are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Surgery, Peritoneal Malignancy Institute, Basingstoke & North Hampshire Hospital, Basingstoke, UK

    Akash M. Mehta MD

  2. Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

    Alwin D. R. Huitema PhD

  3. Department of Surgery, Erasmus MC, Rotterdam, The Netherlands

    Jacobus W. A. Burger MD, PhD & Alexandra R. M. Brandt-Kerkhof MD

  4. Department of Anaesthesiology, Erasmus MC, Rotterdam, The Netherlands

    Sander F. van den Heuvel MD, PhD

  5. Department of Surgery, Aarhus University Hospital, Aarhus, Denmark

    Victor J. Verwaal MD, PhD

Authors
  1. Akash M. Mehta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alwin D. R. Huitema PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacobus W. A. Burger MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandra R. M. Brandt-Kerkhof MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sander F. van den Heuvel MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Victor J. Verwaal MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akash M. Mehta MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mehta, A.M., Huitema, A.D.R., Burger, J.W.A. et al. Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution. Ann Surg Oncol 24, 990–997 (2017). https://doi.org/10.1245/s10434-016-5665-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5665-6

Keywords

Search

Navigation